

Australian Clinical Labs Limited

ABN 62 006 823 089 Registered Office: 1868-1892 Dandenong Road Clayton VIC 3168 Australia

clinicallabs.com.au

Monday, 16 August 2021

ACL FY21 FINANCIAL RESULTS RELEASE DETAILS AND 2021 AGM

FY21 Financial Results

Australian Clinical Labs Limited (ASX: ACL) (**ACL** or **Company**) is pleased to announce that it is planning to release its financial and operating results for the financial year ended 30 June 2021, on Thursday, 26 August 2021.

ACL Chief Executive Officer and Executive Director, Melinda McGrath, and Chief Financial Officer, James Davison, will host an investor webcast at 11am AEST on that day. Webcast details will be provided prior to the event.

2021 AGM

ACL will be holding its inaugural AGM on 27 October 2021 at 10am AEDT. It is currently anticipated that the AGM will be held virtually due to ongoing travel restrictions in respect of COVID-19. A notice of meeting setting out the proposed resolutions and confirming the details for accessing the meeting will be sent to shareholders in due course. Shareholders are reminded that under the Company's constitution any shareholder wishing to nominate themselves or another person as candidate for election as a director must serve a signed notice of nomination and a consent to the nomination on the Company by no later than 35 business days before the AGM, being by no later than 5pm on 7 September 2021.

– ENDS –

This announcement was authorised for release to ASX by the Eleanor Padman, Company Secretary of ACL. For further information regarding this announcement, please contact:

Investors Davina Gunn Investor Relations Email: <u>investors@clinicallabs.com.au</u> Phone: +61 (0) 400 896 809 Company Secretary Eleanor Padman Company Secretary Email: <u>epadman@padmanadvisory.com.au</u> Phone: +61 (0) 422 002 918

About Australian Clinical Labs

ACL is a leading Australian private provider of pathology services. Our 86 NATA accredited laboratories perform a diverse range of pathology tests each year for a range of clients including doctors, specialists, patients, hospitals and corporate clients. ACL is one of the largest private hospital pathology businesses nationally. ACL is focused on its mission of combining talented people, and medical and scientific leadership, with innovative thinking and technologies to empower decision making that saves and improves patients' lives.

Forward looking-statements

This announcement may contain forward-looking statements which are statements that may be identified by words such as "may", "will", "would", "should", "could", "believes", "estimates", "expects", "intends", "plans", "anticipates", "predicts", "outlook", "forecasts", "guidance" and other similar words that involve risks and uncertainties. The upgrade to the FY21 forecast is an example of forward-looking statements. These statements are based on an assessment of present economic and operating conditions and on a number of best estimate assumptions regarding future events and actions that, at the date of this announcement, are expected to take place. No person who has made any forward-looking statements in this announcement (including the Company) has any intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this announcement, other than to the extent required by law. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, the directors and management of the Company. We recommend that shareholders read in conjunction with this announcement Section 4 and Section 5, and other information in the Prospectus. The Company cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statement